ADC Therapeutics (ADCT) Cash & Equivalents (2019 - 2023)
Historic Cash & Equivalents for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $310.4 million.
- ADC Therapeutics' Cash & Equivalents fell 1849.84% to $310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $310.4 million, marking a year-over-year decrease of 1849.84%. This contributed to the annual value of $466544.0 for FY2022, which is 9989.84% down from last year.
- Per ADC Therapeutics' latest filing, its Cash & Equivalents stood at $310.4 million for Q3 2023, which was down 1849.84% from $347.5 million recorded in Q2 2023.
- ADC Therapeutics' 5-year Cash & Equivalents high stood at $530.2 million for Q3 2021, and its period low was $115.55 during Q1 2020.
- In the last 5 years, ADC Therapeutics' Cash & Equivalents had a median value of $466544.0 in 2022 and averaged $145.5 million.
- Per our database at Business Quant, ADC Therapeutics' Cash & Equivalents skyrocketed by 37998758.04% in 2021 and then plummeted by 3003.0% in 2023.
- Quarter analysis of 5 years shows ADC Therapeutics' Cash & Equivalents stood at $115.6 million in 2019, then tumbled by 99.57% to $494416.0 in 2020, then skyrocketed by 92754.75% to $459.1 million in 2021, then dropped by 28.89% to $326.4 million in 2022, then fell by 4.91% to $310.4 million in 2023.
- Its Cash & Equivalents stands at $310.4 million for Q3 2023, versus $347.5 million for Q2 2023 and $326441.0 for Q1 2023.